Avatar photo

Prof. Bugianesi

Prof. Bugianesi

HCC in Patients with NAFLD/NASH

Prof Bugianesi, Italy, reviews a burning issue: hepatocellular carcinoma (HCC) in patients with NAFLD/ NASH. She reviews the epidemiology globally and impact on liver transplant. There are multiple risks factors for HCC in NASH patients such as obesity, type 2 diabetes (T2D), and the metabolic syndrome in general. For clinicians, she presents the main studies, the profiles of the patients particularly at risk and risk stratifications strategies.
Read MoreHCC in Patients with NAFLD/NASH

Prof. Elisabetta Bugianesi MD, PhD, is a clinical researcher graduated at the School of Medicine of the University of Bologna, Italy. Her post-graduate training included a PhD fellowship at the Cleveland Clinic and at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism and started a pioneering research activity on NAFLD under the guidance of Prof AJ McCullough. She is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with about 20-years experience in the field where she has made a particular impact with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease including the first demonstration of HCC as a complication of NASH-related liver disease, the development of non-invasive markers of fibrosis including the NAFLD Fibrosis score, currently recommended by the EASL-EASD-EASO Clinical practice guidelines on NAFLD (J Hepatology, 2016) and the involvement in several trials for the treatment of NAFLD /NASH.